QDEL

20.85

-2.25%↓

NERV

4.08

+0.49%↑

LSTA.US

1.93

-8.96%↓

QDEL

20.85

-2.25%↓

NERV

4.08

+0.49%↑

LSTA.US

1.93

-8.96%↓

QDEL

20.85

-2.25%↓

NERV

4.08

+0.49%↑

LSTA.US

1.93

-8.96%↓

QDEL

20.85

-2.25%↓

NERV

4.08

+0.49%↑

LSTA.US

1.93

-8.96%↓

QDEL

20.85

-2.25%↓

NERV

4.08

+0.49%↑

LSTA.US

1.93

-8.96%↓

Home・Aktien・Pharming Group NV

P
Pharming Group NV

Open

1.415 -2.62

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.395

Max

1.468

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.9M 7.5M
Verkäufe	4.1M 97M
EPS	0.006
Gewinnspanne	7.758
Angestellte	404

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	379M 997M
Vorheriger Eröffnungskurs	4.04
Vorheriger Schlusskurs	1.415

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Nov. 2025, 17:45 UTC

Ergebnisse

Wichtige Markttreiber

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. Nov. 2025, 17:31 UTC

Ergebnisse

Wichtige Markttreiber

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16. Nov. 2025, 23:40 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

16. Nov. 2025, 23:36 UTC

Market Talk

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16. Nov. 2025, 23:26 UTC

Market Talk

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16. Nov. 2025, 16:20 UTC

Ergebnisse

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15. Nov. 2025, 09:20 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

15. Nov. 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15. Nov. 2025, 00:08 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14. Nov. 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. Nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. Nov. 2025, 22:35 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. Nov. 2025, 22:32 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. Nov. 2025, 22:29 UTC

Ergebnisse

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. Nov. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. Nov. 2025, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

14. Nov. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. Nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. Nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. Nov. 2025, 20:17 UTC

Akquisitionen, Fusionen, Übernahmen

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. Nov. 2025, 19:29 UTC

Market Talk

Ergebnisse

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. Nov. 2025, 18:44 UTC

Market Talk

Ergebnisse

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. Nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

14. Nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. Nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. Nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharming Group NV – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.